AZIENDA OSPEDALIERA PAPA GIOVANNI XXIII

Their core work

Papa Giovanni XXIII is a large academic hospital in Bergamo, Italy, operating as a clinical research site for multi-center EU trials across nephrology and cardiology. Their H2020 work focuses on executing Phase 1b/2a clinical trials — enrolling patients, generating safety and efficacy data, and contributing real-world clinical endpoints to research consortia. In NEPHSTROM, they ran a first-in-human trial of mesenchymal stem cell therapy for diabetic kidney disease; in BETA3_LVH, they tested a beta3-adrenergic receptor agonist for cardiac hypertrophy caused by left ventricular dysfunction. They are a site where investigational therapies meet patients, not a basic science laboratory.

What they specialise in

How they've shifted over time

Their first project (NEPHSTROM) planted them firmly in regenerative nephrology — mesenchymal stem cells, immune response mechanisms, and the full chronic kidney disease progression to end-stage renal disease. Their second project (BETA3_LVH) shifted the organ focus entirely to the heart, specifically pharmacological modulation of adrenergic signaling to reverse cardiac hypertrophy and diastolic dysfunction. What remained constant across both is the clinical trial methodology: both are interventional trials testing investigational therapies in human patients. The trajectory suggests the hospital is positioning itself as a general-purpose academic clinical trial site, not a single-disease specialist.

They are moving from rare regenerative medicine trials toward more broadly applicable cardiovascular pharmacology, suggesting a deliberate expansion of their clinical trial portfolio across organ systems.

How they like to work

Papa Giovanni XXIII has participated exclusively as a consortium partner, never as project coordinator — a typical profile for a clinical site that provides patients and clinical infrastructure rather than scientific leadership. Their two projects ran within mid-to-large consortia (30 unique partners across 10 countries), indicating they are comfortable operating within complex multi-site trial networks. For future collaborators, this means they are experienced at following trial protocols written by others and delivering clean clinical data, but they are unlikely to lead a consortium themselves.

Their combined consortia spanned 30 unique partners across 10 countries, a broad geographic spread for just two projects, reflecting the inherently international nature of multi-center clinical trials. No repeated partners are identifiable from this two-project dataset, suggesting they join consortia assembled by external academic or pharma coordinators rather than maintaining a fixed collaboration circle.

What sets them apart

Papa Giovanni XXIII is one of the largest public hospitals in northern Italy, which gives it access to high patient volumes across multiple disease areas — a critical asset for recruiting into interventional clinical trials. Unlike university hospitals that balance teaching with research, this is a pure clinical institution, meaning trial execution and patient care are its core activity rather than a side function. For a consortium needing a credible, high-capacity Italian clinical site with experience in both cardiorenal disease and first-in-human cell therapy, this hospital is a strong candidate.

Highlights from their portfolio

• NEPHSTROM
  This was a first-in-human Phase 1b/2a trial of allogeneic MSC therapy for diabetic kidney disease, making it one of the more clinically ambitious regenerative medicine trials in the H2020 health portfolio — and the hospital's largest single award at EUR 611,472.
• BETA3_LVH
  A multi-center, placebo-controlled randomized trial testing mirabegron — a drug already approved for bladder conditions — as a repurposed treatment for left ventricular hypertrophy, representing a drug repositioning strategy with direct clinical translation potential.